Pulsed intravenous immunoglobulin therapy in refractory ulcerated livedoid vasculopathy

Seven cases and a literature review

Eun Jee Kim, So Young Yoon, Hyun Sun Park, Hyun Sun Yoon, Soyun Cho

Research output: Contribution to journalReview articleResearchpeer-review

8 Citations (Scopus)

Abstract

Livedoid vasculopathy (LV) is a thrombotic vasculopathy of the skin of unknown origin. No treatment has been validated in this indication, but case reports demonstrated successful use of intravenous immunoglobulins (IVIg) in LV. We assessed the efficacy and tolerability of 2 g/kg IVIg therapy every month for 2-3 cycles in patients with refractory LV. We analyzed the efficacy, side effects and recurrence after long-term follow-up (51.9 ± 14.0 months) in seven patients with LV treated with 2 g/kg of IVIg. Mean clinical score of sum of erythema, ulceration and pain index (each: 0-3) was 5.7 ± 0.9 before the therapy and significantly lower after therapy (1.1 ± 0.5) (p = 0.001). Even after just one cycle of IVIg, the score decreased significantly from 5.7 ± 0.9 to 3.7 ± 0.9 (p = 0.002), especially the pain score. In one patient, LV has not recurred for over 7 years; six patients experienced recurrence after a mean of 12.7 ± 2.8 months. Out of the six patients, two patients were re-administered IVIg whereas the others were well controlled by conventional therapy. We propose that IVIg is a rapid, effective, and safe therapeutic option in LV refractory to other treatment modalities.

Original languageEnglish
Pages (from-to)287-290
Number of pages4
JournalDermatologic Therapy
Volume28
Issue number5
DOIs
StatePublished - 1 Sep 2015

Fingerprint

Passive Immunization
Intravenous Immunoglobulins
Therapeutics
Recurrence
Pain
Erythema
Skin

Keywords

  • intravenous immunoglobulin
  • livedoid vasculopathy

Cite this

@article{eacb49104d6d4eecb4dc0de6c421dabd,
title = "Pulsed intravenous immunoglobulin therapy in refractory ulcerated livedoid vasculopathy: Seven cases and a literature review",
abstract = "Livedoid vasculopathy (LV) is a thrombotic vasculopathy of the skin of unknown origin. No treatment has been validated in this indication, but case reports demonstrated successful use of intravenous immunoglobulins (IVIg) in LV. We assessed the efficacy and tolerability of 2 g/kg IVIg therapy every month for 2-3 cycles in patients with refractory LV. We analyzed the efficacy, side effects and recurrence after long-term follow-up (51.9 ± 14.0 months) in seven patients with LV treated with 2 g/kg of IVIg. Mean clinical score of sum of erythema, ulceration and pain index (each: 0-3) was 5.7 ± 0.9 before the therapy and significantly lower after therapy (1.1 ± 0.5) (p = 0.001). Even after just one cycle of IVIg, the score decreased significantly from 5.7 ± 0.9 to 3.7 ± 0.9 (p = 0.002), especially the pain score. In one patient, LV has not recurred for over 7 years; six patients experienced recurrence after a mean of 12.7 ± 2.8 months. Out of the six patients, two patients were re-administered IVIg whereas the others were well controlled by conventional therapy. We propose that IVIg is a rapid, effective, and safe therapeutic option in LV refractory to other treatment modalities.",
keywords = "intravenous immunoglobulin, livedoid vasculopathy",
author = "Kim, {Eun Jee} and Yoon, {So Young} and Park, {Hyun Sun} and Yoon, {Hyun Sun} and Soyun Cho",
year = "2015",
month = "9",
day = "1",
doi = "10.1111/dth.12233",
language = "English",
volume = "28",
pages = "287--290",
journal = "Dermatologic Therapy",
issn = "1396-0296",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "5",

}

Pulsed intravenous immunoglobulin therapy in refractory ulcerated livedoid vasculopathy : Seven cases and a literature review. / Kim, Eun Jee; Yoon, So Young; Park, Hyun Sun; Yoon, Hyun Sun; Cho, Soyun.

In: Dermatologic Therapy, Vol. 28, No. 5, 01.09.2015, p. 287-290.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - Pulsed intravenous immunoglobulin therapy in refractory ulcerated livedoid vasculopathy

T2 - Seven cases and a literature review

AU - Kim, Eun Jee

AU - Yoon, So Young

AU - Park, Hyun Sun

AU - Yoon, Hyun Sun

AU - Cho, Soyun

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Livedoid vasculopathy (LV) is a thrombotic vasculopathy of the skin of unknown origin. No treatment has been validated in this indication, but case reports demonstrated successful use of intravenous immunoglobulins (IVIg) in LV. We assessed the efficacy and tolerability of 2 g/kg IVIg therapy every month for 2-3 cycles in patients with refractory LV. We analyzed the efficacy, side effects and recurrence after long-term follow-up (51.9 ± 14.0 months) in seven patients with LV treated with 2 g/kg of IVIg. Mean clinical score of sum of erythema, ulceration and pain index (each: 0-3) was 5.7 ± 0.9 before the therapy and significantly lower after therapy (1.1 ± 0.5) (p = 0.001). Even after just one cycle of IVIg, the score decreased significantly from 5.7 ± 0.9 to 3.7 ± 0.9 (p = 0.002), especially the pain score. In one patient, LV has not recurred for over 7 years; six patients experienced recurrence after a mean of 12.7 ± 2.8 months. Out of the six patients, two patients were re-administered IVIg whereas the others were well controlled by conventional therapy. We propose that IVIg is a rapid, effective, and safe therapeutic option in LV refractory to other treatment modalities.

AB - Livedoid vasculopathy (LV) is a thrombotic vasculopathy of the skin of unknown origin. No treatment has been validated in this indication, but case reports demonstrated successful use of intravenous immunoglobulins (IVIg) in LV. We assessed the efficacy and tolerability of 2 g/kg IVIg therapy every month for 2-3 cycles in patients with refractory LV. We analyzed the efficacy, side effects and recurrence after long-term follow-up (51.9 ± 14.0 months) in seven patients with LV treated with 2 g/kg of IVIg. Mean clinical score of sum of erythema, ulceration and pain index (each: 0-3) was 5.7 ± 0.9 before the therapy and significantly lower after therapy (1.1 ± 0.5) (p = 0.001). Even after just one cycle of IVIg, the score decreased significantly from 5.7 ± 0.9 to 3.7 ± 0.9 (p = 0.002), especially the pain score. In one patient, LV has not recurred for over 7 years; six patients experienced recurrence after a mean of 12.7 ± 2.8 months. Out of the six patients, two patients were re-administered IVIg whereas the others were well controlled by conventional therapy. We propose that IVIg is a rapid, effective, and safe therapeutic option in LV refractory to other treatment modalities.

KW - intravenous immunoglobulin

KW - livedoid vasculopathy

UR - http://www.scopus.com/inward/record.url?scp=84943818720&partnerID=8YFLogxK

U2 - 10.1111/dth.12233

DO - 10.1111/dth.12233

M3 - Review article

VL - 28

SP - 287

EP - 290

JO - Dermatologic Therapy

JF - Dermatologic Therapy

SN - 1396-0296

IS - 5

ER -